These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26389682)

  • 21. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agitation and aggression in people with Alzheimer's disease.
    Ballard C; Corbett A
    Curr Opin Psychiatry; 2013 May; 26(3):252-9. PubMed ID: 23528917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic treatment of psychosis and agitation in the elderly.
    Daniel DG
    J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care.
    Gallagher D; Herrmann N
    Neurodegener Dis Manag; 2015; 5(1):75-83. PubMed ID: 25711456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
    Viscogliosi G; Chiriac IM; Ettorre E
    J Am Med Dir Assoc; 2017 Sep; 18(9):799-802. PubMed ID: 28739492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of agitation and aggression associated with Alzheimer disease.
    Ballard CG; Gauthier S; Cummings JL; Brodaty H; Grossberg GT; Robert P; Lyketsos CG
    Nat Rev Neurol; 2009 May; 5(5):245-55. PubMed ID: 19488082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist.
    Flint AJ; van Reekum R
    Can J Psychiatry; 1998 Sep; 43(7):689-97. PubMed ID: 9773218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoids for Agitation in Alzheimer's Disease.
    Outen JD; Burhanullah MH; Vandrey R; Amjad H; Harper DG; Patrick RE; May RL; Agronin ME; Forester BP; Rosenberg PB
    Am J Geriatr Psychiatry; 2021 Dec; 29(12):1253-1263. PubMed ID: 33573996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AVP-786 as a promising treatment option for Alzheimer's Disease including agitation.
    Khoury R; Marx C; Mirgati S; Velury D; Chakkamparambil B; Grossberg GT
    Expert Opin Pharmacother; 2021 May; 22(7):783-795. PubMed ID: 33615952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
    Oguma T; Jino K
    Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Literature Review of Methodologies Used in Randomized Clinical Trials of Agitation in Alzheimer's Disease.
    Dubé S; Megerian JT; Malamut R
    J Prev Alzheimers Dis; 2018; 5(2):120-133. PubMed ID: 29616705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AXS-05: an investigational treatment for Alzheimer's disease-associated agitation.
    Ward K; Citrome L
    Expert Opin Investig Drugs; 2022 Aug; 31(8):773-780. PubMed ID: 35763451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia.
    Med Lett Drugs Ther; 2023 Jun; 65(1679):99-101. PubMed ID: 37339089
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.
    Ballard C; Corbett A; Chitramohan R; Aarsland D
    Curr Opin Psychiatry; 2009 Nov; 22(6):532-40. PubMed ID: 19696673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Marinheiro G; Dantas JM; Mutarelli A; Menegaz de Almeida A; Monteiro GA; Zerlotto DS; Telles JPM
    Neurol Sci; 2024 Oct; 45(10):4679-4686. PubMed ID: 38763935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
    Davies SJ; Burhan AM; Kim D; Gerretsen P; Graff-Guerrero A; Woo VL; Kumar S; Colman S; Pollock BG; Mulsant BH; Rajji TK
    J Psychopharmacol; 2018 May; 32(5):509-523. PubMed ID: 29338602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.